secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-069794
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025
-------------------------------------------------------------------------------

- Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.
- Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.
- Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.
- Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.
- R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/0000950170-25-069794-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/itrm-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069794

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer